Skip to search formSkip to main contentSkip to account menu

TTT-3002

Known as: FLT3 Tyrosine Kinase Inhibitor TTT-3002 
An orally bioavailable indolocarbazole derivative and inhibitor of constitutively active mutant forms of FMS-like tyrosine kinase 3 (FLT3) with… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

CarbazolesIndoles
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
FLT3-associated leukemias in vitro and in vivo TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against
http://bloodjournal.hematologylibrary.org/content/123/10/1525.full.html Updated information and services can be found at: (1176… 
2014
2014
Therapeutics , Targets , and Chemical Biology FLT 3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT 3 in Acute Myeloid Leukemia
There have been a number of clinical trials testing the efficacy of FMS-like tyrosine kinase-3 (FLT3) tyrosine kinase inhibitors… 
2013
2013
TTT-3002 Is Active Against Relapsed/Refractory AML Patient Bone Marrow With FLT3 TKI-Resistance Mutations At Residue D835
Over 35% of acute myeloid leukemia (AML) patients harbor a constitutively activating mutation in FLT3 , either internal tandem… 
2012
2012
TTT-3002 Is a Novel FLT3 Tyrosine Kinase Inhibitor That Has the Potential to Overcome Some of the Limitations of Current FLT3 Inhibitors in Treatment of Acute Myeloid Leukemia
Abstract 866 Acute myeloid leukemia (AML) is a hematologic malignancy characterized by increased myeloproliferation and a block… 
2012
2012
Abstract 1807: Characterization of a novel FLT3 inhibitor in AML cell lines
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Acute myeloid leukemia (AML) is a hematologic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)